Your browser doesn't support javascript.
loading
Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.
Xi, Yaming; Jin, Chenghao; Liu, Wei; Zhou, Hu; Wang, Zhen; Zhou, Rongfu; Lou, Shifeng; Zhao, Xielan; Chen, Fangping; Cheng, Peng; Sun, Zimin; Jia, Haifei; Zhang, Lei.
Afiliación
  • Xi Y; Department of Hematology, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China.
  • Jin C; Hemophilia Information Management Center of Jiangxi Province, Jiangxi Provincial People's Hospital, Nanchang, China.
  • Liu W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Di
  • Zhou H; Department of Hematology, The Cancer Hospital affiliated to Zhengzhou University, Zhengzhou, China.
  • Wang Z; Department of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhou R; Department of Hematology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
  • Lou S; Department of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
  • Zhao X; Department of Hematology, Xiangya Hemophilia Diagnosis and Treatment Center, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
  • Chen F; Department of Hematology, Xiangya Hemophilia Diagnosis and Treatment Center, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
  • Cheng P; Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Province, China.
  • Sun Z; Department of Hematology, The Affiliated Provincial Hospital of Anhui Medical University, Hefei, China.
  • Jia H; R&D Institute, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Nanjing, Jiangsu Province, China.
  • Zhang L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Di
Haemophilia ; 28(6): e219-e227, 2022 Nov.
Article en En | MEDLINE | ID: mdl-35996199
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hemostáticos / Hemofilia A Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans / Male Idioma: En Revista: Haemophilia Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hemostáticos / Hemofilia A Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans / Male Idioma: En Revista: Haemophilia Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China